Offbeat F.D.A. names and shames drug makers to encourage generic competition

20:56  17 may  2018
20:56  17 may  2018 Source:   nytimes.com

3 ways Trump could lower drug prices

  3 ways Trump could lower drug prices The president is set to unveil his plan for combating the high cost of prescriptions -- here's where he can get startedWhile much as been said about what the president may or may not propose -- on-script or off -- here's a look a three ways the government could help lower the cost of prescriptions, even in the face of opposition from various interested parties.

Some brand- name drug makers say the legislation is not needed. The F . D . A .’s new list includes drug companies the agency said may be pursuing gaming tactics to delay generic competition .

FDA acts to encourage generic competition for complex drugs . That means patients don't get access to cheaper versions of those drugs and the brand- name medicine makers continue to rake in money, often billions of dollars a year per drug .

a man wearing a suit and tie: Dr. Scott Gottlieb, the F.D.A. commissioner, has vowed to end drug companies’ practice of preventing generic manufacturers from getting samples as a means of lowering drug prices. © Eric Thayer for The New York Times Dr. Scott Gottlieb, the F.D.A. commissioner, has vowed to end drug companies’ practice of preventing generic manufacturers from getting samples as a means of lowering drug prices.

Pharmaceutical companies that spend billions of dollars to develop new drugs do not want competitors to profit from inexpensive generic copies of blockbuster medicines. To avoid rivals, they fight for patent extensions, seek new uses for old products and, sometimes, prevent generic drug companies from obtaining samples.

Dr. Scott Gottlieb, the commissioner of the Food and Drug Administration, calls this “gaming the system,” and has vowed to stop it as part of the government’s campaign to lower drug prices.

6 Takeaways From Trump’s Plans to Try to Lower Drug Prices

  6 Takeaways From Trump’s Plans to Try to Lower Drug Prices The drug industry won some key victories, even if it did not escape entirely unscathed. Many proposals were light on detail and will need action by Congress to become real.Yet Mr. Trump won some praise for having taken a stab at tackling such a complex and vitally important issue to many Americans.Here is a rundown of the key proposals unveiled on Friday.Lower drug prices for older peopleOn the campaign trail, Mr.

Often, they don't get generic competition right after their patent expires, as happens routinely with pills. Now, Brozak said, he's telling brand- name drugmakers to focus on developing new drugs , not wringing extra money out of blockbusters long on the market, while encouraging generic makers .

Often, they don't get generic competition right after their patent expires, as happens routinely with pills. Now, Brozak said, he's telling brand- name drugmakers to focus on developing new drugs , not wringing extra money out of blockbusters long on the market, while encouraging generic makers .

On Thursday, the F.D.A. took a new tack and began posting a list of makers of brand-name drugs that have been the target of complaints, to persuade them to “end the shenanigans,” in the commissioner’s words.

Dr. Gottlieb calls it transparency, but this approach is better known among ethicists as naming and shaming.

Congressional efforts to force the companies to hand over samples of their drugs to generic competitors have not been successful. Recent proposals to ensure generic access to drug samples would save the federal government $3.8 billion over 10 years, according to the Congressional Budget Office, partly by lowering Medicare and Medicaid spending on prescription drugs.

The Federal Trade Commission has also been investigating the practice.

What Trump is quietly (and effectively) doing to fix our broken health care system

  What Trump is quietly (and effectively) doing to fix our broken health care system Since ObamaCare’s passage and failed implementation, patient premiums and out of pocket expenses have gone way up, not down as promised. Consumers now have fewer options in terms of policies and benefits to choose from, not more as they were told.  Countless patients can no longer see their doctors or be treated at local facilities of their choice. On the campaign trail, candidate Donald Trump said he would work with a Republican Congress to repeal ObamaCare so that patients and doctors, rather than bureaucrats and unelected boards, would have more control over individuals’ health care decisions.

The FDA is currently working to reduce high drug costs by encouraging the development of generic versions of hard-to-make medicines. That means patients don’t get access to cheaper verisons of those drugs and brand- name medicine makers continue to rake in money, often billions of dollars a

FDA Commissioner Scott Gottlieb has proposed publicly shaming brand- name drug companies that try to thwart competition from generics. By 2016, it had jumped to 0. A lower-cost generic wasn’t an option because Celgene, the drug ’s manufacturer, refused to provide samples to generics makers for

Some brand-name drug makers say the legislation is not needed. The F.D.A. has been speeding up approval of generic drugs, and nearly 90 percent of prescriptions are filled with generic drugs.

Sign up for the Morning Briefing newsletter

But others point to the ways in which major pharmaceutical companies have managed to keep patents on certain expensive drugs for years longer than necessary.

Generic drug developers usually need between 1,500 to 5,000 units of the brand drug to develop their product and test it, to show that it is effective and can be absorbed at the same rate as the brand drug, according to the agency. Both the F.D.A. and the Federal Trade Commission say securing the samples can be difficult, because major drug firms can invoke safety concerns — real or unreal — to avoid providing the materials.

The F.D.A.’s new list includes drug companies the agency said may be pursuing gaming tactics to delay generic competition. Along with the name of each business, the agency noted how many inquiries it received from generic drug companies seeking supplies. The names of the generic companies were not provided.

Trump to Drop Call for Medicare to Negotiate Lower Drug Prices

  Trump to Drop Call for Medicare to Negotiate Lower Drug Prices Breaking a campaign promise, President Trump will not push for the plan, which was popular with voters but not other Republican politicians, when he speaks on Friday about soaring prescription costs.WASHINGTON — President Trump will lay out on Friday a broad strategy to reduce prescription drug prices, but in a break from one of his most popular campaign promises, he will not call for Medicare to negotiate lower prices with drug manufacturers, senior administration officials said.

Now, Brozak said, he's telling brand- name drugmakers to focus on developing new drugs , not wringing extra money out of blockbusters long on the market, while encouraging generic makers . "Nothing in health care is instantaneous," Brozak said

Often, they don’t get generic competition right after their patent expires, as happens routinely with pills. Now, Brozak said, he’s telling brand- name drugmakers to focus on developing new drugs , not wringing extra money out of blockbusters long on the market, while encouraging generic makers .

While Celgene tops the list, other companies that the F.D.A. named as the subject of complaints included GlaxoSmithKline, Pfizer, Valeant Pharmaceuticals International, BioMarin Pharmaceutical, Gilead Sciences and Novartis Pharmaceuticals.

Celgene, which makes drugs to treat cancer and immune-inflammatory diseases, was named as the subject of 31 inquiries from companies seeking access to Revlimid (lenalidomide), its treatment for multiple myeloma and related diseases; Pomalyst (pomalidomide); and Thalomid (thalidomide).

Celgene has been embroiled in lawsuits for several years with companies seeking access to the drugs. It recently sued Dr. Reddy’s Laboratories Ltd., an Indian company, to block it from selling generic copies of Revlimid, the company’s biggest product, and has been fending off an attempt by Mylan to also get into the generic Revlimid business. At a court hearing last year, a lawyer for Mylan, Jonathan M. Jacobson, told a federal district judge that the drug costs dying patients $20,000 a month — a price that would decline if generics were available.

Trump outlines plan to lower drug prices

  Trump outlines plan to lower drug prices The president said he would promote more competition, but broke with the promises that he made while campaigning, like calling for Medicare to negotiate lower prices.WASHINGTON — President Trump vowed on Friday to “derail the gravy train for special interests” as he outlined a strategy intended to lower the cost of prescription drugs by promoting tougher negotiation, more competition and measures to stop foreign countries from taking advantage of American industry.

The issue of brand- name drug makers thwarting generic competition cropped up in connection with Turing Pharmaceuticals when it was run by Martin Shkreli. Watchdog says Vertex cystic fibrosis drugs are not cost effective, but company calls analysis a ‘ sham ’.

Often, they don't get generic competition right after their patent expires, as happens routinely with pills. Now, Brozak said, he's telling brand- name drugmakers to focus on developing new drugs , not wringing extra money out of blockbusters long on the market, while encouraging generic makers .

Greg Geissman, a spokesman for Celgene, said the company had not prevented generic companies from obtaining their products.

“We have sold and will sell our groundbreaking products to generic manufacturers for the purposes of bioequivalence testing, subject to reasonable safety-related and business requirements,” Mr. Geissman said. “Generic versions of Thalomid and Revlimid are expected to enter the market in coming years.”

Geissman also said that Celgene supports federal efforts to promote access to samples at reasonable prices, as long as there is appropriate safety and liability protection for the seller.

The next biggest target, with 26 inquiries, is Actelion Pharmaceuticals Ltd., a Johnson & Johnson company, which is accused of blocking access to four drugs. There were 14 inquiries about getting supplies of Tracleer (bosentan), a medication prescribed for high blood pressure in the vessels of the lungs, known as pulmonary arterial hypertension. The F.D.A. also received eight complaints about lack of access to Opsumit (macitentan), which is also used to treat pulmonary arterial hypertension. There were also several complaints about a lack of access to Actelion’s Zavesca (miglustat) and Veletri (epoprostenol sodium). Veletri is also used to treat pulmonary arterial hypertension and Zavesca is indicated for Gaucher disease.

An average one-month supply of Tracleer costs just over $12,000, and a supply of Opsumit runs $8,900 to $10,000, according to GoodRx, which tracks drug prices. Both prices are based on the patient presenting a free discount coupon.

Many pharmaceutical companies sell both brand-name and generic drugs, leading to a situation in which a company like Mylan, still fighting Celgene in court, can be on the receiving end of generic company complaints.

The F.D.A.’s list of shame notes three inquiries from companies trying to get access to Mylan’s Amnesteem (isotretinoin), used to treat severe cystic acne that has not responded to antibiotic treatment.

Trump lays out his plan to tackle high drug prices .
President Donald Trump spoke Friday about ways to lower the price of prescription drugs. Trump focused on finding ways to increase competition, get more negotiating power, and finding ways to lower pharmaceutical list prices as well as the out-of-pocket costs patients are facing according to senior administration officials familiar with the speech.

Source: http://us.pressfrom.com/news/offbeat/-145828-f-d-a-names-and-shames-drug-makers-to-encourage-generic-competition/

—   Share news in the SOC. Networks

Topical videos:

This is interesting!